Efficacy of antiresorptive agents in fibrous dysplasia and McCune Albright syndrome, a systematic review and meta-analysis.
Antiresorptive
Bisphosphonates
Denosumab
Fibrous dysplasia of bone
McCune-Albright syndrome
Meta-analysis
Journal
Reviews in endocrine & metabolic disorders
ISSN: 1573-2606
Titre abrégé: Rev Endocr Metab Disord
Pays: Germany
ID NLM: 100940588
Informations de publication
Date de publication:
12 2023
12 2023
Historique:
accepted:
10
08
2023
medline:
6
12
2023
pubmed:
27
8
2023
entrez:
26
8
2023
Statut:
ppublish
Résumé
Fibrous dysplasia (FD) is a rare skeletal disorder in which normal bone is replaced by a fibro-osseous tissue, resulting in possible deformities and fractures. The aim of this systematic review and meta-analysis was to synthesize the available evidence on the use of antiresorptive drugs in FD in terms of changes in bone turnover markers (BTMs), bone mineral density (BMD), and reducing pain. Three databases were searched in October 2022, with an update in July 2023. Of the 1037 studies identified, 21 were retained after eligibility assessment. A random-effects model was used to calculate global effect size and the corresponding standard error. Pamidronate and Denosumab were the most reported drugs in a total of 374 patients assessed. The initiation of treatments was accompanied by an average reduction of 40.5% [CI
Identifiants
pubmed: 37632645
doi: 10.1007/s11154-023-09832-2
pii: 10.1007/s11154-023-09832-2
doi:
Substances chimiques
Bone Density Conservation Agents
0
Diphosphonates
0
Types de publication
Meta-Analysis
Systematic Review
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1103-1119Subventions
Organisme : Fondation des Gueules Cassées
ID : 2018-51
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Lietman SA, Levine MA. Fibrous dysplasia. Pediatr Endocrinol Rev PER. 2013;10(Suppl 2):389–96.
pubmed: 23858622
Chapurlat RD, Orcel P. Fibrous dysplasia of bone and McCune-Albright syndrome. Best Pract Res Clin Rheumatol. 2008;22:55–69. https://doi.org/10.1016/j.berh.2007.11.004 .
doi: 10.1016/j.berh.2007.11.004
pubmed: 18328981
Boyce AM, Collins MT. Fibrous Dysplasia/McCune-Albright Syndrome: A Rare, Mosaic Disease of Gα s Activation. Endocr Rev. 2020;41:345–70. https://doi.org/10.1210/endrev/bnz011 .
doi: 10.1210/endrev/bnz011
pubmed: 31673695
Weinstein LS, Shenker A, Gejman PV, Merino MJ, Friedman E, Spiegel AM. Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N Engl J Med. 1991;325:1688–95. https://doi.org/10.1056/NEJM199112123252403 .
doi: 10.1056/NEJM199112123252403
pubmed: 1944469
Landis CA, Masters SB, Spada A, Pace AM, Bourne HR, Vallar L. GTPase inhibiting mutations activate the alpha chain of Gs and stimulate adenylyl cyclase in human pituitary tumours. Nature. 1989;340:692–6. https://doi.org/10.1038/340692a0 .
doi: 10.1038/340692a0
pubmed: 2549426
Hu Q, Shokat KM. Disease-Causing Mutations in the G Protein Gαs Subvert the Roles of GDP and GTP. Cell. 2018;173:1254-1264.e11. https://doi.org/10.1016/j.cell.2018.03.018 .
doi: 10.1016/j.cell.2018.03.018
pubmed: 29628140
pmcid: 5959768
de Castro LF, Burke AB, Wang HD, Tsai J, Florenzano P, Pan KS, et al. Activation of RANK/RANKL/OPG Pathway Is Involved in the Pathophysiology of Fibrous Dysplasia and Associated With Disease Burden. J Bone Miner Res Off J Am Soc Bone Miner Res. 2019;34:290–4. https://doi.org/10.1002/jbmr.3602 .
doi: 10.1002/jbmr.3602
Riminucci M, Kuznetsov SA, Cherman N, Corsi A, Bianco P, Gehron RP. Osteoclastogenesis in fibrous dysplasia of bone: in situ and in vitro analysis of IL-6 expression. Bone. 2003;33:434–42.
doi: 10.1016/S8756-3282(03)00064-4
pubmed: 13678786
Takeuchi T, Yoshida H, Tanaka S. Role of interleukin-6 in bone destruction and bone repair in rheumatoid arthritis. Autoimmun Rev. 2021;20:102884. https://doi.org/10.1016/j.autrev.2021.102884 .
Javaid MK, Boyce A, Appelman-Dijkstra N, Ong J, Defabianis P, Offiah A, et al. Best practice management guidelines for fibrous dysplasia/McCune-Albright syndrome: a consensus statement from the FD/MAS international consortium. Orphanet J Rare Dis. 2019;14:139. https://doi.org/10.1186/s13023-019-1102-9 .
doi: 10.1186/s13023-019-1102-9
pubmed: 31196103
pmcid: 6567644
Burke AB, Collins MT, Boyce AM. Fibrous dysplasia of bone: craniofacial and dental implications. Oral Dis. 2017;23:697–708. https://doi.org/10.1111/odi.12563 .
doi: 10.1111/odi.12563
pubmed: 27493082
Hart ES, Kelly MH, Brillante B, Chen CC, Ziran N, Lee JS, et al. Onset, progression, and plateau of skeletal lesions in fibrous dysplasia and the relationship to functional outcome. J Bone Miner Res Off J Am Soc Bone Miner Res. 2007;22:1468–74. https://doi.org/10.1359/jbmr.070511 .
doi: 10.1359/jbmr.070511
Parisi MS, Oliveri B. Long-term pamidronate treatment of polyostotic fibrous dysplasia of bone: A case series in young adults. Curr Ther Res Clin Exp. 2009;70:161–72. https://doi.org/10.1016/j.curtheres.2009.03.003 .
doi: 10.1016/j.curtheres.2009.03.003
pubmed: 24683227
pmcid: 3967299
Bertin H, Huon JF, Guillot P, Longis J, Corre P, Bordereau S, et al. Fibrous dysplasia of the orbital region: Series of 12 cases and review of the literature. J Fr Ophtalmol. 2020;43:467–76. https://doi.org/10.1016/j.jfo.2019.10.012 .
doi: 10.1016/j.jfo.2019.10.012
pubmed: 32376037
Wang Y, Wang O, Jiang Y, Li M, Xia W, Meng X, et al. Efficacy and safety of bisphosphonate therapy in mccune-albright syndrome–related polyostotic fibrous dysplasia: A single-center experience. Endocr Pr. 2019;25:23–30. https://doi.org/10.4158/EP-2018-0328 .
doi: 10.4158/EP-2018-0328
Chapurlat RD, Hugueny P, Delmas PD, Meunier PJ. Treatment of fibrous dysplasia of bone with intravenous pamidronate: long-term effectiveness and evaluation of predictors of response to treatment. Bone. 2004;35:235–42. https://doi.org/10.1016/j.bone.2004.03.004 .
doi: 10.1016/j.bone.2004.03.004
pubmed: 15207763
Chapurlat RD, Delmas PD, Liens D, Meunier PJ. Long-term effects of intravenous pamidronate in fibrous dysplasia of bone. J Bone Min Res. 1997;12:1746–52. https://doi.org/10.1359/jbmr.1997.12.10.1746 .
doi: 10.1359/jbmr.1997.12.10.1746
Liens D, Delmas PD, Meunier PJ. Long-term effects of intravenous pamidronate in fibrous dysplasia of bone. Lancet. 1994;343:953–4. https://doi.org/10.1016/S0140-6736(94)90069-8 .
doi: 10.1016/S0140-6736(94)90069-8
pubmed: 7909013
Boyce AM, Kelly MH, Brillante BA, Kushner H, Wientroub S, Riminucci M, et al. A randomized, double blind, placebo-controlled trial of alendronate treatment for fibrous dysplasia of bone. J Clin Endocrinol Metab. 2014;99:4133–40. https://doi.org/10.1210/jc.2014-1371 .
doi: 10.1210/jc.2014-1371
pubmed: 25033066
pmcid: 4223439
Chapurlat R, Legrand MA. Bisphosphonates for the treatment of fibrous dysplasia of bone. Bone. 2021;143. https://doi.org/10.1016/j.bone.2020.115784 .
Majoor BCJ, Papapoulos SE, Sander Dijkstra PD, Fiocco M, Hamdy NAT, Appelman-Dijkstra NM. Denosumab in Patients with Fibrous Dysplasia Previously Treated with Bisphosphonates. J Clin Endocrinol Metab. 2019;104:6069–78. https://doi.org/10.1210/jc.2018-02543 .
doi: 10.1210/jc.2018-02543
pubmed: 31390018
Meier ME, Clerkx SN, Winter EM, Pereira AM, van de Ven AC, van de Sande MAJ, et al. Safety of therapy with and withdrawal from denosumab in fibrous dysplasia and McCune-Albright syndrome: an observational study. J Bone Min Res. 2021;36:1729–38. https://doi.org/10.1002/jbmr.4380 .
doi: 10.1002/jbmr.4380
de Castro LF, Michel Z, Pan K, Taylor J, Szymczuk V, Paravastu S, et al. Safety and Efficacy of Denosumab for Fibrous Dysplasia of Bone. N Engl J Med. 2023;388:766–8. https://doi.org/10.1056/NEJMc2214862 .
doi: 10.1056/NEJMc2214862
pubmed: 36812441
pmcid: 10015375
Valadares LP, de Araújo Ferreira BS, da Cunha BM, Moreira LA, Batista FGA, da Fonseca Hottz C, et al. Effects of zoledronic acid therapy in fibrous dysplasia of bone: a single-center experience. Arch Endocrinol Metab. 2022;66:247–55. https://doi.org/10.20945/2359-3997000000459 .
Tripathy S, Swaroop S, Velagada S, Priyadarshini D, Das R, Satpathy A, et al. Response to Zoledronic Acid Infusion in Children With Fibrous Dysplasia. Front Pediatr. 2020;8. https://doi.org/10.3389/fped.2020.582316 .
Chapurlat RD, Meunier PJ. Fibrous dysplasia of bone. Baillieres. Best Pract Res Clin Rheumatol. 2000;14:385–98. https://doi.org/10.1053/berh.1999.0071 .
doi: 10.1053/berh.1999.0071
Florenzano P, Pan KS, Brown SM, Guthrie LC, De Castro LF, Collins MT, et al. Age-related changes and the effect of bisphosphonates on bone turnover and disease progression in fibrous dysplasia of bone. J Bone Min Res. 2018;33:121.
Lala R, Matarazzo P, Andreo M, Marzari D, Bellone J, Corrias A, et al. Bisphosphonate treatment of bone fibrous dysplasia in McCune-Albright syndrome. J Pediatr Endocrinol Metab. 2006;19:583–93.
doi: 10.1515/JPEM.2006.19.S2.583
pubmed: 16789621
Plotkin H, Rauch F, Zeitlin L, Munns C, Travers R, Glorieux FH. Effect of Pamidronate Treatment in Children with Polyostotic Fibrous Dysplasia of Bone. J Clin Endocrinol Metab. 2003;88:4569–75. https://doi.org/10.1210/jc.2003-030050 .
doi: 10.1210/jc.2003-030050
pubmed: 14557424
Isaia GC, Lala R, Defilippi C, Matarazzo P, Andreo M, Roggia C, et al. Bone turnover in children and adolescents with Mccune-Albright syndrome treated with pamidronate for bone fibrous dysplasia. Calcif Tissue Int. 2002;71:121–8. https://doi.org/10.1007/s00223-001-1098-7 .
doi: 10.1007/s00223-001-1098-7
pubmed: 12200645
Zacharin M, O’Sullivan M. Intravenous pamidronate treatment of polyostotic fibrous dysplasia associated with the McCune Albright syndrome. J Pediatr. 2000;137:403–9. https://doi.org/10.1067/mpd.2000.107836 .
doi: 10.1067/mpd.2000.107836
pubmed: 10969268
Pfeilschifter J, Ziegler R. Effects of pamidronate on clinical symptoms and bone metabolism in patients with fibrous dysplasia and McCune-Albright-syndrome. Wirk Von Pamidronat Auf Beschwerdebild Knochenstoffwechsel Bei Fibroser Dysplasie McCune-Albright-Syndr. 1998;93:352–9. https://doi.org/10.1007/bf03044679 .
doi: 10.1007/bf03044679
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https://doi.org/10.1136/bmj.n71 .
Clark JM, Sanders S, Carter M, Honeyman D, Cleo G, Auld Y, et al. Improving the translation of search strategies using the Polyglot Search Translator: a randomized controlled trial. J Med Libr Assoc JMLA. 2020;108:195–207. https://doi.org/10.5195/jmla.2020.834 .
doi: 10.5195/jmla.2020.834
pubmed: 32256231
Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014;14:135. https://doi.org/10.1186/1471-2288-14-135 .
doi: 10.1186/1471-2288-14-135
pubmed: 25524443
pmcid: 4383202
Stavnichuk M, Mikolajewicz N, Corlett T, Morris M, Komarova SV. A systematic review and meta-analysis of bone loss in space travelers. NPJ Microgravity. 2020;6:13. https://doi.org/10.1038/s41526-020-0103-2 .
doi: 10.1038/s41526-020-0103-2
pubmed: 32411816
pmcid: 7200725
Boot AM, de Ridder MA, Pols HA, Krenning EP, de Muinck Keizer-Schrama SM. Bone mineral density in children and adolescents: relation to puberty, calcium intake, and physical activity. J Clin Endocrinol Metab. 1997;82:57–62. https://doi.org/10.1210/jcem.82.1.3665 .
doi: 10.1210/jcem.82.1.3665
pubmed: 8989233
National Institutes of Health (NIH). Quality Assessment Tool for Before-After (Pre-Post) Studies with No Control Group. 2013.
Ozdemir Kutbay N, Sarer Yurekli B, Kartal Baykan E, Baydur Sahin S, Saygili F. Characteristics and treatment results of 5 patients with fibrous Dysplasia and review of the literature. Case Rep Endocrinol. 2015;2015. https://doi.org/10.1155/2015/670809 .
Van Der Bruggen W, Vriens D, Meier ME, Smit F, Winter EM, De Geus-Oei L-F, et al. Denosumab Reduces Lesional Fluoride Skeletal Burden on Na[18F]F PET-CT in Patients with Fibrous Dysplasia/McCune-Albright Syndrome. J Clin Endocrinol Metab. 2021;106:E2980–94. https://doi.org/10.1210/clinem/dgab212 .
doi: 10.1210/clinem/dgab212
pubmed: 33788944
pmcid: 8277209
Parisi MS, Oliveri B, Mautalen CA. Effect of intravenous pamidronate on bone markers and local bone mineral density in fibrous dysplasia. Bone. 2003;33:582–8. https://doi.org/10.1016/S8756-3282(03)00221-7 .
doi: 10.1016/S8756-3282(03)00221-7
pubmed: 14555262
Lane JM, Khan SN, O’Connor WJ, Nydick M, Hommen JP, Schneider R, et al. Bisphosphonate therapy in fibrous dysplasia. Clin Orthop Relat Res. 2001;382:6–12. https://doi.org/10.1097/00003086-200101000-00003 .
doi: 10.1097/00003086-200101000-00003
Trojani MC, Gensburger D, Bagouet F, Cortet B, Couture G, Marcelli C, et al. Denosumab use in bone fibrous dysplasia refractory to bisphosphonate: A retrospective multicentric study. Bone. 2023;174:116819. https://doi.org/10.1016/j.bone.2023.116819 .
Thomsen MD, Rejnmark L. Clinical and radiological observations in a case series of 26 patients with fibrous dysplasia. Calcif Tissue Int. 2014;94:384–95. https://doi.org/10.1007/s00223-013-9829-0 .
doi: 10.1007/s00223-013-9829-0
pubmed: 24390518
Chakraborty PP, Biswas SN, Patra S, Santra G. “Zebra Stripe” Sign and “Bone in Bone” Sign in Cyclical Bisphosphonate Therapy. J Clin Diagn Res. 2017;11:RJ01–2. https://doi.org/10.7860/JCDR/2017/24349.9177 .
Majoor BC, Appelman-Dijkstra NM, Fiocco M, van de Sande MA, Dijkstra PS, Hamdy NA. Outcome of Long-Term Bisphosphonate Therapy in McCune-Albright Syndrome and Polyostotic Fibrous Dysplasia. J Bone Miner Res Off J Am Soc Bone Miner Res. 2017;32:264–76. https://doi.org/10.1002/jbmr.2999 .
doi: 10.1002/jbmr.2999
Raborn LN, Burke AB, Ebb DH, Collins MT, Kaban LB, Boyce AM. Denosumab for craniofacial fibrous dysplasia: duration of efficacy and post-treatment effects. Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA. 2021;32:1889–93. https://doi.org/10.1007/s00198-021-05895-6 .
doi: 10.1007/s00198-021-05895-6
Tucker-Bartley A, Selen DJ, Golden E, van Gool R, Ebb D, Mannstadt M, et al. Pharmacological Interventions Targeting Pain in Fibrous Dysplasia/McCune-Albright Syndrome. Int J Mol Sci. 2023;24:2550. https://doi.org/10.3390/ijms24032550 .
doi: 10.3390/ijms24032550
pubmed: 36768871
pmcid: 9916440
Huzum B, Antoniu S, Dragomir R. Treatment of fibrous dysplasia: focus on denosumab. Expert Opin Biol Ther. 2022;22:397–405. https://doi.org/10.1080/14712598.2022.2022118 .
doi: 10.1080/14712598.2022.2022118
pubmed: 34964677
Chapurlat R, Gensburger D, Trolliet C, Rouanet S, Mehsen-Cetre N, Orcel P. Inhibition of IL-6 in the treatment of fibrous dysplasia of bone: the randomized double-blind placebo-controlled TOCIDYS trial. Bone. 2022;157:116343. https://doi.org/10.1016/j.bone.2022.116343 .
Robinson C, Collins MT, Boyce AM. Fibrous Dysplasia/McCune-Albright Syndrome: Clinical and Translational Perspectives. Curr Osteoporos Rep. 2016;14:178–86. https://doi.org/10.1007/s11914-016-0317-0 .
doi: 10.1007/s11914-016-0317-0
pubmed: 27492469
pmcid: 5035212
Saggio I. Perils and Promises of Therapeutic Approaches for the Stem Cell Disease Fibrous Dysplasia. Stem Cells Transl Med. 2019;8:110–1. https://doi.org/10.1002/sctm.18-0213 .
doi: 10.1002/sctm.18-0213
pubmed: 30426717
Lv M, Li X, Huang Y, Wang N, Zhu X, Sun J. Inhibition of fibrous dysplasia via blocking Gsα with suramin sodium loaded with an alendronate-conjugated polymeric drug delivery system. Biomater Sci. 2016;4:1113–22. https://doi.org/10.1039/c6bm00091f .
doi: 10.1039/c6bm00091f
pubmed: 27180636
Khan SK, Yadav PS, Elliott G, Hu DZ, Xu R, Yang Y. Induced GnasR201H expression from the endogenous Gnas locus causes fibrous dysplasia by up-regulating Wnt/β-catenin signaling. Proc Natl Acad Sci USA. 2018;115:E418–27. https://doi.org/10.1073/pnas.1714313114 .
doi: 10.1073/pnas.1714313114
pubmed: 29158412
Shen L, He Y, Chen S, He L, Zhang Y. PTHrP Modulates the Proliferation and Osteogenic Differentiation of Craniofacial Fibrous Dysplasia-Derived BMSCs. Int J Mol Sci. 2023;24:7616. https://doi.org/10.3390/ijms24087616 .
doi: 10.3390/ijms24087616
pubmed: 37108778
pmcid: 10146947
Fontalis A, Eastell R. The challenge of long-term adherence: The role of bone turnover markers in monitoring bisphosphonate treatment of osteoporosis. Bone. 2020;136:115336. https://doi.org/10.1016/j.bone.2020.115336 .
Schini M, Vilaca T, Gossiel F, Salam S, Eastell R. Bone Turnover Markers: Basic Biology to Clinical Applications. Endocr Rev. 2022:bnac031. https://doi.org/10.1210/endrev/bnac031 .
Winter EM, Kooijman S, Appelman-Dijkstra NM, Meijer OC, Rensen PC, Schilperoort M. Chronobiology and Chronotherapy of Osteoporosis. JBMR Plus. 2021;5:e10504. https://doi.org/10.1002/jbm4.10504 .
Meier ME, Hagelstein-Rotman M, Streefland TCM, Winter EM, Bravenboer N, Appelman-Dijkstra NM. Clinical value of RANKL, OPG, IL-6 and sclerostin as biomarkers for fibrous dysplasia/McCune-Albright syndrome. Bone. 2023:116744. https://doi.org/10.1016/j.bone.2023.116744 .
van der Bruggen W, Hagelstein-Rotman M, de Geus-Oei L-F, Smit F, Dijkstra PDS, Appelman-Dijkstra NM, et al. Quantifying skeletal burden in fibrous dysplasia using sodium fluoride PET/CT. Eur J Nucl Med Mol Imaging. 2020;47:1527–37. https://doi.org/10.1007/s00259-019-04657-1 .
doi: 10.1007/s00259-019-04657-1
pubmed: 31875244
Legrand MA, Millet M, Merle B, Rousseau JC, Hemmendinger A, Gineyts E, et al. A Signature of Circulating miRNAs Associated With Fibrous Dysplasia of Bone: the mirDys Study. J Bone Miner Res Off J Am Soc Bone Miner Res. 2020;35:1881–92. https://doi.org/10.1002/jbmr.4111 .
doi: 10.1002/jbmr.4111
Collins MT, Kushner H, Reynolds JC, Chebli C, Kelly MH, Gupta A, et al. An instrument to measure skeletal burden and predict functional outcome in fibrous dysplasia of bone. J Bone Miner Res Off J Am Soc Bone Miner Res. 2005;20:219–26. https://doi.org/10.1359/JBMR.041111 .
doi: 10.1359/JBMR.041111
Jreige M, Hall N, Becce F, Aubry-Rozier B, Gonzalez Rodriguez E, Schaefer N, et al. A novel approach for fibrous dysplasia assessment using combined planar and quantitative SPECT/CT analysis of Tc-99m-diphosphonate bone scan in correlation with biological bone turnover markers of disease activity. Front Med. 2022;9:1050854. https://doi.org/10.3389/fmed.2022.1050854 .
doi: 10.3389/fmed.2022.1050854
Weidner LD, Wakabayashi Y, Stolz LA, Collins MT, Guthrie L, Victorino M, et al. PET Imaging of Phosphodiesterase-4 Identifies Affected Dysplastic Bone in McCune-Albright Syndrome, a Genetic Mosaic Disorder. J Nucl Med Off Publ Soc Nucl Med. 2020;61:1672–7. https://doi.org/10.2967/jnumed.120.241976 .
doi: 10.2967/jnumed.120.241976
Wang Y, Wu J, Liu L, Peng D, Chen Y. 68Ga-FAPI-04 PET/CT Imaging for Fibrous Dysplasia of the Bone. Clin Nucl Med. 2022;47:e9-10. https://doi.org/10.1097/RLU.0000000000003896 .
doi: 10.1097/RLU.0000000000003896
pubmed: 34507335
Pozzessere C, Cicone F, Barberio P, Papa A, Coppolino G, Biagini R, et al. Cross-sectional evaluation of FGD-avid polyostotic fibrous dysplasia: MRI, CT and PET/MRI findings. Eur J Hybrid Imaging. 2022;6:19. https://doi.org/10.1186/s41824-022-00139-0 .
doi: 10.1186/s41824-022-00139-0
pubmed: 36184649
pmcid: 9527265
Majoor BCJ, Traunmueller E, Maurer-Ertl W, Appelman-Dijkstra NM, Fink A, Liegl B, et al. Pain in fibrous dysplasia: relationship with anatomical and clinical features. Acta Orthop. 2019;90:401–5. https://doi.org/10.1080/17453674.2019.1608117 .
doi: 10.1080/17453674.2019.1608117
pubmed: 31035847
pmcid: 6718189
Chapurlat RD, Gensburger D, Jimenez-Andrade JM, Ghilardi JR, Kelly M, Mantyh P. Pathophysiology and medical treatment of pain in fibrous dysplasia of bone. Orphanet J Rare Dis. 2012;7(Suppl 1):S3. https://doi.org/10.1186/1750-1172-7-S1-S3 .
doi: 10.1186/1750-1172-7-S1-S3
pubmed: 22640953
pmcid: 3359957
Spencer TL, Watts L, Soni A, Pinedo-Villanueva R, Heegaard A-M, Boyce AM, et al. Neuropathic-like Pain in Fibrous Dysplasia/McCune-Albright Syndrome. J Clin Endocrinol Metab. 2022;107:e2258–66. https://doi.org/10.1210/clinem/dgac120 .
doi: 10.1210/clinem/dgac120
pubmed: 35262711
pmcid: 9113795
Rijks EBG, Bongers BC, Vlemmix MJG, Boot AM, van Dijk ATH, Sakkers RJB, et al. Efficacy and Safety of Bisphosphonate Therapy in Children with Osteogenesis Imperfecta: A Systematic Review. Horm Res Paediatr. 2015;84:26–42. https://doi.org/10.1159/000381713 .
doi: 10.1159/000381713
pubmed: 26021524
Rotman M, Hamdy NAT, Appelman-Dijkstra NM. Clinical and translational pharmacological aspects of the management of fibrous dysplasia of bone. Br J Clin Pharmacol. 2019;85:1169–79. https://doi.org/10.1111/bcp.13820 .
doi: 10.1111/bcp.13820
pubmed: 30471134
Colloca L. The Placebo Effect in Pain Therapies. Annu Rev Pharmacol Toxicol. 2019;59:191–211. https://doi.org/10.1146/annurev-pharmtox-010818-021542 .
doi: 10.1146/annurev-pharmtox-010818-021542
pubmed: 30216744
Oo WM, Hunter DJ. Nerve Growth Factor (NGF) Inhibitors and Related Agents for Chronic Musculoskeletal Pain: A Comprehensive Review. BioDrugs Clin Immunother Biopharm Gene Ther. 2021;35:611–41. https://doi.org/10.1007/s40259-021-00504-8 .
doi: 10.1007/s40259-021-00504-8
de Almeida AS, Pereira GC, da Brum ES, Silva CR, de Antoniazzi CTD, Ardisson-Araujo D, et al. Role of TRPA1 expressed in bone tissue and the antinociceptive effect of the TRPA1 antagonist repeated administration in a breast cancer pain model. Life Sci. 2021;276:119469. https://doi.org/10.1016/j.lfs.2021.119469 .
Daut RL, Cleeland CS, Flanery RC. Development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases. Pain. 1983;17:197–210. https://doi.org/10.1016/0304-3959(83)90143-4 .
doi: 10.1016/0304-3959(83)90143-4
pubmed: 6646795
Sampayo-Cordero M, Miguel-Huguet B, Pardo-Mateos A, Moltó-Abad M, Muñoz-Delgado C, Pérez-López J. Agreement between the results of meta-analyses from case reports and from clinical studies regarding the efficacy of laronidase therapy in patients with mucopolysaccharidosis type I who initiated enzyme replacement therapy in adult age: An example of case reports meta-analyses as an useful tool for evidence-based medicine in rare diseases. Mol Genet Metab. 2018;123:69–75. https://doi.org/10.1016/j.ymgme.2018.01.002 .
doi: 10.1016/j.ymgme.2018.01.002
pubmed: 29336994